TTK has been described to activate AURKB through the phosphorylation of borealin during chromosome alignment [5] and, consequently, treatment of cancer cells with TTKi leads to the inhibition of AURKB, as evidenced by a decrease in phosphor-histone H3 levels [60]. The gene discussed is TTK; the disease is cancer.